CMEA Capital
VC Fund
San Francisco, United States
CMEA Capital is a VC fund in San Francisco focused on Biotechnology and Software. CMEA closed in April of 2015 and has unveiled its new corporate identity as [Presidio Partners](https://www.crunchbase.com/organization/presidio-partners). CMEA Capital is a venture capital firm with a clear focus on life sciences, high technology, and energy and materials investments. We believe that the most successful venture backed companies are those that are science based, with experienced teams that have a vision. As a result, CMEA typically invests in companies that have cutting edge and highly differentiated technology at their core and founding teams of the highest caliber still in place. These are companies that have the potential to transform their industries. CMEA Capital was founded in 1989 and maintains offices in San Francisco and Menlo Park. We invest in both early and late stage science-focused ventures, and leverage a strong network of corporate, investment, and entrepreneurial relationships on behalf of portfolio companies. Our partners and associates have extensive science, engineering, and operational backgrounds, providing us the confidence to look beyond today's technology. We apply our focus on science and teams to our collaborations with entrepreneurs and venture investment partners who are changing the world, one great company at a time.
- Total investments:
- 63
- Last investment:
- Lead investor:
- 21%
- Fund size:
- $400M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries CMEA Capital invests in
Stages CMEA Capital invests in
Countries CMEA Capital invests in
Round sizes
Round size
- Series A
- $424k–$15M
- Series B
- $8M–$30M
- Series C
- $2.7M–$45M
Investment Focus
Industry
- Biotechnology 11 (17%)
- Software 9 (14%)
- Health Care 9 (14%)
- Manufacturing 7 (11%)
- Energy 5 (8%)
Stage
- Series C 14 (22%)
- Series B 12 (19%)
- Series A 10 (16%)
- Series D 9 (14%)
- Funding Round 7 (11%)
Country
- United States 39 (62%)
- United Kingdom 1 (2%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| VYNE Therapeutics is a clinical late-stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. We are concurrently evaluating the use of serlopitant for refractory chroniccough, a cough that persists for greater than eight weeks despite treatment of any identified underlying cause. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor (NK1-R) given as a once-daily, oral tablet, has the potential to significantly alleviate pruritus and refractory chronic cough symptoms. Pruritus is the primary patient complaint among atopic dermatitis, psoriasis and prurigo nodularis patients and represents a significant patient need. There are currently no therapies approved in the US that are primarily intended to reduce the pruritus associated with these conditions. We expect data from our ongoing Phase 2 clinical trial in pruritus associated with atopic dermatitis in the 2Q18 and from our ongoing Phase 2 clinical trials in pruritus associated with psoriasis and refractory chronic cough by late 2018 or early 2019. We plan to initiate two Phase 3 clinical trials in pruritus associated with prurigo nodularis in the 1H18, with results expected in the 1H20. | $14.3M / Series A / May 01, 2015 | ||
| Beijing Cnano Technology Co. Ltd. is dedicated to the production of carbon nanotubes and application of advanced energy that includes the application of lithium battery, conductive plastics, and mechanical structures. It is the Chinese branch of the Cnano Company. On the basis of acquiring the exclusive licensing of a patent from TsinghuaUniversity, in combination with its own internal technological innovation, Cnano Technology has developed a large-batch production technology of carbon nano-tubes. Headquartered in Santa Clara, California, USA, Cnano Technology has established advanced research and manufacturing facilities in Beijing, China. | $15M / Series B / Apr 20, 2015 | ||
| Jobvite is leading the next wave of talent acquisition innovation with a candidate-centric recruiting model that helps companies engage candidates with meaningful experiences at the right time, in the right way, from first look to first day. The Jobvite Talent Acquisition Suite weaves together automation and intelligence in order to increaserecruiting speed, quality, and cost-effectiveness to serve thousands of customers of all sizes and industries. | $25M / Series D / Oct 07, 2014 | ||
| Sorbent Therapeutics, Inc. develops treatment for end stage renal disease patients undergoing dialysis. The company develops fluid retaining polymers for therapeutic uses, such as treatment of kidney diseases. Sorbent Therapeutics, Inc. was founded in 2005 and is based in Vernon Hills, Illinois. | Series D / May 15, 2014 | ||
| Arcadia Biosciences is an agricultural technology company focused on developing products that benefit the environment and human health. The company uses advanced screening, breeding and biotechnology techniques (both GM and non-GM) to create value for consumers, processors and farmers. | $33M / Series D / May 08, 2014 | ||
| The Neos Therapeutics team is dedicated to creating high-quality products and partnering with pharmaceutical and consumer healthcare companies to address key medical needs.Neos Therapeutics’ research and development (R&D) and fully integrated state of the art, FDA approved manufacturing facility is located in the Dallas/Fort Wortharea. | $15.5M / Series C / Mar 04, 2014 | ||
| Auspex Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of orphan diseases. The company's pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea associated with Huntington’s disease, tardivedyskinesia, and Tourette syndrome, as well as other orphan indications. | $20M / Series E / Jan 08, 2014 | ||
| MediaSpike provides a native monetization platform for applications, with a focus on social and mobile games. For application developers, integration involves using one of the MediaSpike SDKs to interact with the MediaSpike backend. Brands and agencies can then search by several parameters for appropriate placements through the MediaSpikedashboard.Placements are made by selecting an available placement, uploading the appropriate asset(s), previewing the placement and then submitting the placement to the developer through the MediaSpike dashboard.Once submitted a placement is reviewed and approved by the developer. Analytics for live placements are tracked and viewable through the MediaSpike dashboard. | $5.2M / Series A / Nov 04, 2013 | ||
| The Future of Cloud WiFiAt Mojo Networks, we are leading a revolution in cloud managed WiFi services and products for enterprise wireless. Existing architectures are antiquated. Controllers will soon be obsolete. We make it simple to move your massive enterprise WLAN to the cloud with automation and built-in scaling.Mojo's cloud WiFiplatform is easy to deploy and intuitive to manage while also enabling advanced features like graphical troubleshooting, WiFi user analytics and social engagement. Above all, we continue to advance our widely acknowledged industry-leading security capabilities. We've secured the air and built our cloud designed for a new frontier of prolific connectivity.Prolific – We want seamless connectivity for everyone, everywhere, all the time. Manage your Mojo Networks WiFi products from anywhere in the world – no controllers required.Intuitive – Our access points and sensors are programmed out-of-the-box to automatically discover and connect to the Mojo Networks cloud wireless platform. Deployment and management is a piece of cake.Responsive – Most of the time the Mojo Networks cloud managed WiFi platform works like magic, but when it doesn’t, we respond immediately to do what’s right for our customers.Trustworthy – The credibility of our top-ranked wireless intrusion prevention system (WIPS) is proven every day from the highest levels of government to the infrastructure of developing nations.At Mojo Networks, we are obsessive with making our customers successful. We are committed to fearless creativity and partnering with others who share the same passion. | $10M / Series D / Jul 15, 2013 | ||
| MediaSpike provides a native monetization platform for applications, with a focus on social and mobile games. For application developers, integration involves using one of the MediaSpike SDKs to interact with the MediaSpike backend. Brands and agencies can then search by several parameters for appropriate placements through the MediaSpikedashboard.Placements are made by selecting an available placement, uploading the appropriate asset(s), previewing the placement and then submitting the placement to the developer through the MediaSpike dashboard.Once submitted a placement is reviewed and approved by the developer. Analytics for live placements are tracked and viewable through the MediaSpike dashboard. | Seed / Jul 10, 2012 | ||
| See all 63 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does CMEA Capital invest in?
CMEA Capital invests primarily in Biotechnology, Software and Health Care startups, most often at Series C and Series B stage. Most of the 63 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does CMEA Capital invest in?
CMEA Capital typically joins rounds of $424k–$15M at Series A, $8M–$30M at Series B and $2.7M–$45M at Series C. These are whole funding-round sizes, not CMEA Capital's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds CMEA Capital took part in.
When did CMEA Capital last invest?
The most recent investment recorded for CMEA Capital closed in May 2015. Shizune tracks 63 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
